Percutaneous Mechanical Circulatory Support Devices Market to Grow at 12.3+% CAGR to Reach 2,977.8 Mn by 2025 Led by Abbott, Medtronic, Getinge AB, Teleflex Incorporated, LivaNova PLC, ABIOMED

The global percutaneous mechanical circulatory support devices market accounted to US$ 1,188.2 Mn in 2017 and is expected to grow at a CAGR of 12.3% during the forecast period 2018 - 2025, to account to US$ 2,977.8 Mn by 2025.

Asia-Pacific was the leading geographic market and it is anticipated to be the highest revenue contributor throughout the forecast period. Higher concentration of small scale industries in the developing countries like India and China, is expected to fuel percutaneous mechanical circulatory support devices market in this region.

New Intelligence Report on “Percutaneous Mechanical Circulatory Support Devices Market to 2027” is recently published by The Insight Partners. The report aims to provide leading industry players with information such as company profiles, products and services offered, financial information of last 3 years, key development in past five years

Ask for a Sample of this Report Now at: http://bit.ly/2VVqSTw

Key Benefits:
• To provide detailed information regarding the major factors (drivers, restraints, opportunities, challenges, and trends) influencing the growth of the global Percutaneous Mechanical Circulatory Support Devices Market
• To forecast the size of the market segments with respect to four major regional segments, namely, North America, Europe, Asia Pacific, and the Rest of the World (Latin America and the Middle East & Africa)

Some of the Major Players In Percutaneous Mechanical Circulatory Support Devices Market:
• Abbott
• Medtronic
• Getinge AB
• Teleflex Incorporated
• LivaNova PLC
• ABIOMED
• EUROSETS
• Berlin Heart
• Jarvik Heart, Inc.
• CardioBridge GmbH

An exclusive Percutaneous Mechanical Circulatory Support Devices Market research report created through broad primary research (inputs from industry experts, companies and stakeholders) and secondary research, the report aims to present the analysis of Global Percutaneous Mechanical Circulatory Support Devices Market By Type, By Application, By Region - North America, Europe, South America, Asia-Pacific, Middle East and Africa. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global Percutaneous Mechanical Circulatory Support Devices Market. Additionally, the report also highlights market entry strategies for various companies across the globe.

Patients with advanced heart failure have a poor prognosis and heart transplant is still the best treatment option. However, the scarcity of donors, long waiting times, and an increasing number of unstable patients have favored the development of mechanical circulatory support. Moreover, according to the Heart Failure Society of America, nearly 5.7 million Americans are suffering from heart failure. The data also suggests that almost 1.4 million persons with CHF are under 60 years of age. Thus, the solution to this shortage of heart donors served by the temporarily used percutaneous mechanical circulatory support devices that are also helpful in long-term support for patients suffering with heart failures are likely to be adopted at higher rates in the coming years.

Strategic Insights
Product approval and acquisition were observed as the most adopted strategy in global percutaneous mechanical circulatory support devices industry. Few of the recent product approvals and acquisitions are listed below:

2018: Abbott received approval for the HeartMate 3 Left Ventricular Assist Device (LVAD) as a destination therapy for people living with advanced heart failure. With the approval, physicians can now offer the HeartMate 3 system to patients not eligible for a transplant who will live with their device for the rest of their lives.

2018: Teleflex Incorporated received FDA 510 (k) clearance for its Arrow AC3 Optimus intra-aortic balloon pump. The device is designed to help weakened hearts pump blood and can deliver IABP therapy to a broad range of patients, including candidates who had previously not been considered for IABP therapy.

2018: Medtronic completed acquisition of HeartWare International, Inc., a leading innovator of less-invasive, miniaturized, mechanical circulatory support technologies (MCS) for treating patients with advanced heart failure.

Inquiry for Discount: http://bit.ly/2Zvp7yO

PERCUTANEOUS MECHANICAL CIRCULATORY SUPPORT DEVICES - MARKET SEGMENTATION

By Product
• Intra-Aortic Balloon Pumps
• VA-Extracorporeal Membrane Oxygenation (ECMO)
o Oxygenators
o Short-term Ventricular Assist Devices
o Impella
o TandemHeart

By End User
• Hospitals
• Ambulatory Surgical Centers
• Others

By Geography
• North America
o U.S.
o Canada
o Mexico
• Europe
o France
o Germany
o UK
o Rest of Europe
• Asia Pacific (APAC)
o China
o India
o Japan
o Rest of APAC
• Middle East & Africa (MEA)
o Saudi Arabia
o South Africa
o UAE
o Rest of MEA
• South America (SAM)
o Brazil
o Rest of SAM

Direct Purchase a copy of this report at: http://bit.ly/2UK9eWx

About Us
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services.

We are committed to providing highest quality research and consulting services to our customers. We help our clients understand key market trends, identify opportunities, and make informed decisions by providing market research solutions at an affordable cost.

Contact us
The Insight partners,
Phone: +1-646-491-9876
Email: sales@theinsightpartners.com
Home: https://www.theinsightpartners.com

This release was published on openPR.